Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities

2 maanden geleden Economie

Dit is een origineel bericht van
PR Newswire

BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ -- Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to significant improvements in physical functioning, such as climbing stairs and tying your shoes, and beneficial effects on weight related and health related quality of life scores (HRQoL) compared to placebo.* Following the 68-week treatment period, more than half of participants had improved quality of life scores, indicating better physical function and improved psychological wellbeing.([1]) The results from the STEP 1 trial will be presented today at the virtual European Congress on Obesity (ECO) 2021 Annual Meeting.

"Weight management is much more than achieving weight loss. We should also aim to improve the impairments that accompany elevated weight such as decreased physical functioning," said Dr Sean Wharton of the Wharton Medical Clinic, Toronto, Canada and an investigator of this study. "It is encouraging to see that the significant weight loss achieved in STEP 1 had such a positive impact on people's wellbeing and their ability to perform daily physical activities, such as taking walks and going about their daily routines."

Obesity is becoming one of the most important global health concerns, with more than 650 million people living with obesity worldwide.([2]) The risk factors of obesity and overweight, such as increased risk of type 2 diabetes and cardiovascular disease, are well-documented. However, often obesity has a significant negative impact on people's wellbeing affecting their physical and psychological health and limiting their daily activities.([3])

"I am really proud of these results. Obesity is not only about the weight itself; living with this chronic disease affects all aspects of a person's life such as not being able to climb stairs or move around as part of one's daily routines," said Martin Holst Lange, executive vice president, Development at Novo Nordisk. "This has implications both for physical and mental health. This study shows that treatment with semaglutide 2.4 mg improves mental and physical wellbeing. It holds real potential to improve the lives of people living with obesity."

Data Details

In the phase 3a STEP 1 trial, treatment with once-weekly semaglutide 2.4 mg over a 68-week period was associated with greater improvements for all weight- and health-related quality of life scores((A)) in people with obesity or overweight, compared to placebo. People on semaglutide 2.4 mg had an improved wellbeing such as feeling more energetic and more self-confident, with 43.8% achieving a clinically meaningful improvement in total weight-related quality of life score((B)) at week 68. In addition, more than half of people (51.2%) treated with semaglutide 2.4 mg had an increased weight-related physical function score indicating improvements in the ability to perform daily physical activities such as tying their shoe and walking to the shops. These improvements occurred simultaneously with the significant weight loss of 14.9% (16.9% with the trial product estimand) observed with semaglutide 2.4 mg over more than a year.([4] )

The safety profile of semaglutide 2.4 mg is in line with observations seen previously with glucagon-like peptide-1 (GLP-1) receptor agonists. Semaglutide 2.4 mg is generally well-tolerated, and the most common adverse events among people treated with semaglutide 2.4 mg were gastrointestinal events.([1,5])

About STEP 1 and the STEP clinical trial programme

STEP 1 was a 68-week phase 3a randomised, double-blind, multicentre, placebo-controlled trial that investigated the percentage change in body weight and the number of people achieving 5% or more weight reduction with subcutaneous semaglutide 2.4 mg versus placebo, in conjunction with lifestyle intervention. The trial was designed to assess the effect of once-weekly semaglutide 2.4 mg plus lifestyle intervention on sustained, clinically relevant reduction in body weight in adults with a body mass index of >=30 or >=27 in people with >=1 weight-related coexisting condition. Participants were randomly assigned (in a 2:1 ratio) to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention (counselling and a reduced-calorie diet together with 150 minutes per week of physical activity).([1,5])

STEP (Semaglutide Treatment Effect in People with obesity) is a phase 3 clinical development programme with once-weekly subcutaneous semaglutide 2.4 mg in obesity. The global clinical phase 3a programme consists of four trials and has enrolled approximately 4,500 adults with overweight or obesity.([6]) In the STEP trials, the primary estimand (treatment policy estimand) assessed effects regardless of treatment adherence or initiation of other anti-obesity therapies. The secondary estimand (trial product estimand) assessed effects if all people adhered to treatment and did not initiate other anti-obesity therapies.

In the phase 3a STEP 1 trial, people on semaglutide 2.4 mg experienced significant improvements in weight-related quality of life, with 43.8% achieving clinically meaningful improvement in total weight-related quality of life score((B)) of >=16.6 points at week 68. In addition, 51.2% of people treated with semaglutide 2.4 mg achieved clinically meaningful improvement in weight-related physical function score (>=14.6 points) compared to 32.9% with placebo. Changes in health-related quality of life scores((C)), such as physical functioning and social functioning, were higher and favoured semaglutide versus placebo.([5]) Similarly, 40% of participants achieved clinical meaningful improvement in health-related physical functioning score (>=3.7 points), compared to 27% with placebo.([1,5]) These improvements were observed using patient-reported outcome methods commonly used in clinical trials for people with obesity.

About subcutaneous semaglutide 2.4 mg for weight management

Once-weekly semaglutide 2.4 mg is under investigation for chronic weight management and not yet approved for people with obesity. It is currently under regulatory review in several countries, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Semaglutide is an analogue of the human glucagon-like peptide-1 (GLP-1) hormone, with 94% similarity to the native human GLP-1 molecule.([7,8]) It induces weight loss by reducing hunger, increasing feeling of fullness and thereby helping people eat less and reduce their food cravings.([7])

About obesity

Obesity is a chronic disease that requires long-term management.([9,10]) It is associated with many serious health complications and decreased life expectancy.([11,12]) Obesity-related complications are numerous and include type 2 diabetes,([10]) heart disease,([10] )obstructive sleep apnoea,([13]) non-alcoholic fatty liver disease([14]) and certain types of cancer.([15]) The current COVID-19 pandemic has highlighted that obesity also increases the risk for severe illness and hospitalisation due to COVID-19.([16,17])

The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. In 2016, 13% of adults, or approximately 650 million adults, were living with obesity worldwide.([18])

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit, Facebook, Twitter, LinkedIn, YouTube.

*The STEP trial participants were adults with a body-mass index of 30 or greater (Obesity) (>=27 in persons with >=1 weight-related coexisting condition (overweight). A. Weight and health related quality of life improvements were assessed using patient reported outcomes tools including Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) and Short Form 36 (SF-36) questionnaires B. IWQOL-Lite-CT is a questionnaire assessing the effect of weight on various areas of life such as physical function, self-esteem, public distress, sexual life and work; scores range from 0 to 100, with higher scores indicating better levels of functioning C. SF-36 is a 36-item questionnaire evaluating health-related quality of life including physical functioning, bodily pain, role limitations due to physical health problems, emotional well-being, and social functioning; scores range from 0 to 100, with higher scores indicating favourable health status.


1. Wharton S, Bjorner JB, Kushner RF, et al. Semaglutide 2.4 mg Once Weekly Improves Patient-Reported Outcome Measures of Physical Functioning in Adults with Overweight or Obesity in the STEP 1 Trial. Presented at ECO 2021, May 10-13. 2. World Health Organization. Obesity and Overweight Factsheet no. 311. Available at: . Last accessed: May 2021. 3. Phelan S, Burgess DJ, Yeazel MW, et al. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obesity Reviews. 2015; 16:319-326. 4. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384:989. 5. Rubino DM, Bjorner JB, Kushner RF, et al. Beneficial Effect of Semaglutide 2.4 mg Once Weekly on Patient-Reported Outcome Measures of Weight-Related and Health-Related Quality of Life in Adults With Overweight or Obesity in the STEP 1 Trial. Presented at ECO 2021, 10-13 May. 6. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020; 28:1050-1061. 7. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; 19:1242-1251. 8. Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015; 58:7370-7380. 9. Wadden TA, et al. Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial. Obesity 2019;21:75-86. 10. WHO. Obesity: Preventing and managing the global epidemic. Available at: . Last accessed: May 2021. 11. Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003; 138:24-32. 12. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:88. 13. Gami AS, Caples SM and Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003; 32:869-894. 14. Vernon G, Baranova A and Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34:274-285. 15. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373:1083-1096. 16. Finer N, Garnett SP and Bruun JM. COVID-19 and obesity. Clin Obes. 2020; 10:e12365. 17. Ryan DH, Ravussin E and Heymsfield S. COVID 19 and the Patient with Obesity - The Editors Speak Out. Obesity (Silver Spring). 2020; 28:847. 18. Durrer Schutz D, Busetto L, Dicker D, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019; 12:40-66. CONTACT: Further information: Media: Mette Kruse Danielsen, +45 3079 3883,; Michael Bachner (US), +1 609 664 7308, Investors: Daniel Muusmann Bohsen, +45 3075 2175;; Valdemar Borum Svarrer, +45 3079 0301,; Ann Søndermølle Rendbæk, +45 3075 2253,; David Heiberg Landsted, +45 3077 6915,; Mark Joseph Root (US), +1 848 213 3219,

Web site:

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Andere persberichten van deze organisatie

The Yang Guoqiang family comes in fourth on 2021 Forbes China Philanthropy List

This marks the 13th time that the family has been included in the list

FOSHAN, China, July 24, 2021 /PRNewswire/ -- Country Garden founder and chairman Yang Guoqiang and his family were China's fourth most generous providers of charitable cash donations in 2021 according to the 2021 China Philanthropy List released by Forbes China on July 20, with the founder and family having donated 2.38 billion yuan (approx. US$357 million). This is the 13th time that the Yang family has been included in the list, reflecting his continuous contributions to worthwhile causes.

Over the past 20+ years, the Yang Guoqiang family, Country Garden Group and Guangdong Guoqiang Public Welfare Foundation have donated in the aggregate of over 9 billion yuan (approx. US$1.3 billion) for poverty alleviation, vocational education, teaching and scientific research, helping lift more than 490,000 underprivileged people out of poverty.

Based on the notion that knowledge can change our fate, the three entities have been involved in poverty alleviation through their support of educational programs over the past 24 years.

In 1997, Mr. Yang donated 1 million yuan (approx. US$150,000), half of his total wealth at the time, to set up the Zhongming Grant Program, an effort designed to fund economically disadvantaged yet outstanding university students. In 2002, he once again gave half of his net worth (260 million yuan (approx. US$39 million)) to establish Guohua Memorial Middle School, the only private high school in China that provides free education and accommodations to needy students who came from all over the country to join the curriculum.

Notably, with the launch of the grant program, the charity schools and the events in support of education, he has helped change the fate of over 100,000 underprivileged students through education. In addition, the Yang Guoqiang family has invested more than 1.1 billion yuan (approx. US$165 million) to establish Guangdong Country Garden Polytechnic and Gansu Linxia Guoqiang Vocational Technical School, both of which provide skills training to students of limited means, in an effort to not only facilitate the expansion of vocational education facilities but also deepen the involvement of companies and organizations across a wide swath of industries into the educational process.

"I used to be a poor student. I couldn't have finished high school without grants from the government," said Mr. Yang. "The government's reform and opening-up policies have given me an opportunity to give back to society, and I have taken this mission on as a personal responsibility."

As the Yang family's fortunes have continued to grow, the family, Country Garden Group and Guangdong Guoqiang Public Welfare Foundation have deepened their efforts in doing away with poverty with the launch of projects to help those less fortunate in 57 counties across 16 provinces. In addition, they are exploring a replicable, effective and sustainable model for reducing poverty by providing targeted assistance in matters of education and employment, as well as facilitating the engagement of the corporate world in these efforts and working in concert with the Party to do so. Building on its success in poverty alleviation, Country Garden Group has shifted its focus to rural revitalization, with the aim of creating an effective model that involves businesses as well as organizations and that promotes the cultivation of talented individuals. The model also facilitates a better understanding of the importance of culture and ecology while opening up a path by which private enterprises can do its bit to help revitalize rural areas.

In February 2021, Mr. Yang was awarded the title of "National Advanced Individual in Poverty Alleviation" for his outstanding contribution to poverty reduction. This follows his garnering of the China Poverty Eradication Award for Innovation in 2015 and the National Poverty Alleviation Award for Outstanding Contribution in 2016. In October 2019, his daughter, Yang Huiyan, who is also Country Garden Group's co-chairperson, was honored with the 2019 National Poverty Alleviation Award for Outstanding Contribution following the receipt of the China Charity Award for Special Contribution in 2008 and the China Charity Award for Individuals in 2018.

Photo - Photo -

CONTACT: Media Contact:Xiaohong Shi, +86-13760809178

8 uur geleden

Tokyo 2020 Olympic Games - Jumping Preview

Jumping looks set to be a testing thriller

LAUSANNE, Switzerland, July 23, 2021 /PRNewswire/ -- Tokyo 2020 is one of the most talked-about Olympic Games of all time, and as it arrives a year late and filled with challenges, for the stars of international Jumping the questions are clear: How will the three-rider no-drop-score format play out in the battle for the Team medals? And is there anyone to get in the way of the pair who claimed individual silver at the FEI World Equestrian Games in 2018 and the individual European title a year later - Martin Fuchs and his super-horse Clooney - when it comes to individual gold? ]

With so few team competition opportunities in the lead-up to these Games, it's difficult to make any predictions, but if the Division 1 Nations Cups that took place last month are anything to go by, then the on-form countries are Sweden, Switzerland, Germany and the Netherlands.

A total of 75 athletes will be chasing down their individual dreams when the action begins at Baji Koen on 3 August, and athletes from 19 countries will be giving it everything they've got when the team contest gets underway on 6 August. It will be a fascinating four days of Olympic equestrian sport.

Team France are the defending champions having clinched gold for only the second time in Olympic history in Rio 2016, and Penelope Leprevost is the only member of that victorious team to line out again at Tokyo 2020 where she will be joined by Mathieu Billot and Nicolas Delmotte. Silver went to the USA five years ago, while Germany won out in a thrilling jump-off against Canada for the bronze.

Comeback king Nick Skelton won Britain's first Olympic Individual title in Rio with Big Star, a phenomenal and emotional achievement for the 58-year-old who had broken his neck in a fall 16 years earlier. Silver went to Sweden's Peder Fredricson and the brilliant All In and this pair, who won individual European gold in 2017, will be joined by Malin Baryard-Johnson (Indiana) and Henrik von Eckermann (King Edward) in Tokyo.

The British have two of the team that secured Olympic gold for their country for the first time in 60 years in London 2012, and both Scott Brash (Hello Jefferson) and Ben Maher (Explosion W) also look set to challenge strongly for the individual medals.



Images available on FEI Flickr for editorial use only.

FEI Social Media

Facebook, Instagram, Twitter, FEI-YouTube

#EquestrianShowjumping #Showjumping #Equestrian #Tokyo2020 #Olympics

Video content All video footage is available at with the following login details: Password: FEI2018

Media Toolkit View the FEI Equestrian Media Toolkit here

Follow all media updates and competition results throughout the Games.

Click here for more information on Equestrian at the Olympic Games.

About FEI

Media contact:

Shannon Gibbons FEI Media Relations & Media Operations Manager +41 78 750 61 46

Photo - Logo - ]

15 uur geleden

SI Group Signs Agreement To Sell Industrial Resins Business To ASK Chemicals

Agreement Includes Products, Technology, and Manufacturing Assets in Brazil, India & South Africa

SCHENECTADY, N.Y., July 23, 2021 /PRNewswire/ -- SI Group, a leading performance additives company, announced today plans to complete an agreement to sell the majority of its global Industrial Resins business to ASK Chemicals, a portfolio company of private equity firm, Rhône Group, LLC.

The transaction includes SI Group's Industrial Resins products and associated manufacturing sites in Rio Claro, Brazil; Ranjangaon, India; and Johannesburg, South Africa, as well as licensed technology and multiple tolling agreements globally. ASK Chemicals, headquartered in Hilden, Germany, is a market leader in the foundry materials sector and manufactures binders, coatings, feeders, filters, and release agents, as well as metallurgical products including inoculants, inoculation wires and master alloys for iron casting.

"We remain confident this is the right strategic move for our employees and our business. ASK Chemicals has proven industry expertise that will add significant value and continuously enhance these businesses," said David Bradley, President & CEO of SI Group. "The deal also allows us to focus more intentionally on building and growing our portfolio as a performance additives powerhouse."

SI Group will carve out related businesses at these sites, including the manufacture of Rubber & Adhesives, Oilfield, and Surfactants, as well as Foundry products in Brazil, and will operate tolling agreements with ASK. The company will also retain the Industrial Resins businesses in the U.S. and China.

About SI Group

SI Group is a global leader in the innovative technology of performance additives, process solutions, active pharmaceutical ingredients, and chemical intermediates. SI Group solutions are essential to enhancing the quality and performance of countless industrial and consumer goods within the plastics, rubber & adhesives, fuels & lubricants, oilfield, pharmaceutical, and industrial resins industries. Headquartered in Schenectady, New York, SI Group's global manufacturing footprint includes 24 facilities on five continents, serving customers in 90 countries with 2,800 employees worldwide. SI Group innovates and drives change to create value with a passion for safety, chemistry, and extraordinary results. Learn more at

Media Contact: Joseph Grande ph: + 1.413.684.2463

Logo -

15 uur geleden

Violette becomes Guerlain Creative Director of Makeup

PARIS, July 23, 2021 /PRNewswire/ -- With her creativity, daring, Parisian chic, eye for high standards and genuine sense of commitment, Violette seemed destined to join a House synonymous with French beauty and constant innovation, still emphasizing modernity despite being over 190 years old.

To view the Multimedia News Release, please click:

"My story with Guerlain is really the story of my femininity... As a little girl, Météorites with its little pastel-coloured pearls for the complexion had a real aesthetic impact on me. I'd stare at the box fascinated, I couldn't wait to become a woman... I pictured myself at my dressing table putting on lipstick, perfume and dipping a brush into these incredible Météorites. Today, I've been invited to write the next chapter in Guerlain's history as Director of Makeup. That's the magic of beauty."

Of Guerlain, Violette says: "Guerlain is a woman! A modern Empress... and a Parisienne, right down to her fingertips. I'm so happy to be joining an iconic House with such a rich heritage, where I can pass Guerlain's values in makeup on to a new generation and share it with those who, no matter their gender, celebrate beauty today and will celebrate it tomorrow.

As a pioneer, the Guerlain House must show commitment by becoming environmentally involved and engaging with femininity in broad and diverse way."

When it comes to Violette's philosophy "the sky's the limit", or in other words "nothing's impossible". As a young woman she's made a place for herself within the makeup world. And as a French woman she gained recognition in the United States within just a few months of moving there on a whim in 2015 (her astrological sign is Aries, which explains her tenacity and taste for risk). She has collaborated with major houses since the beginning of her career (namely with Dior as a Makeup Designer and more recently with Estée Lauder, where she held the post of Global Beauty Director at just 33 years old.) Violette has succeeded in making a name for herself - a first name at that - thereby inscribing her work into the annals of contemporary beauty. Her world is a unique and fertile one, where her spontaneous creativity, Parisian sensibilities, masterful techniques and love of art are blended together.

"Just like Guerlain, I think of art as an inexhaustible source of inspiration. I'm used to saying that art is the love of my life."

Her portfolio is filled with thousands of images from collaborations with renowned magazines including Vogue, Harper's Bazaar, W Magazine, T Magazine, Dazed, Teen Vogue and Elle. And while fashion photography may be her playground of choice, she knows better than anyone else that makeup is nothing if not the art of bringing out the beauty in each and every one of us. With many followers across social media (namely 400k followers on Instagram) she created her own Violette_fr YouTube channel 6 years ago to share makeup tutorials and beauty snapshots.

For a woman who applies makeup with such effortlessness and ease, sharing her experiences with a passionate community of fans was instinctive. Which is why she launched her own line of makeup in April 2021, named quite naturally VIOLETTE_FR.

Today, Guerlain and Violette will start writing a new chapter in the history of beauty. As a duo.

Logo: Photo:


UK: Joanna Sophia Rash PR Manager

USA : Alexa Cohen Senior Manager, Communications & Makeup

CONTACT: UK Office: 0207 563 7560, Mobile: 07767 248102, US Tel. : +1 (212) 931 1318 Cell: +1 (508) 733 3719

17 uur geleden

THC BioMed Announces Shipment to Yukon


VANCOUVER, BC, July 23, 2021 /PRNewswire/ -- THC BioMed Intl Ltd. ("THC BioMed" or the "Company" is pleased to announced that it has completed its first shipment to Yukon Cannabis. The shipment contains dried cannabis and cannabis cookies.

About THC

THC BioMed is one of Canada's oldest active licensed cannabis companies. THC BioMed is a Cannabis Act Licensed Producer of medical and recreational cannabis.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

Contact : President and CEO: John Miller, THC Biomed Intl Ltd., T: 1-844-THCMEDS, E:

Web site:

19 uur geleden

GWM POER Lure International Championship Closes, Creating All-scenario Life

BAODING, China, July 23, 2021 /PRNewswire/ -- On July 16, the first match of the 2021 GWM POER Lure International Championship closed successfully. The Championship attracted many highly-skilled Lure contestants and audiences from various circles of interest. Covered by more than 350 media and live-streamed across the Internet, the Championship became a hit.

Lure fishing started in North America and has become a global popular competitive sport after 40 years' development. It is loved by fishing enthusiasts. Lure enthusiasts have to carry professional equipment and Lure boats and trek over mountains and water. Therefore, pickups that can go off-road, tow and load should be a must-have for them. GWM POER's independent and open trunk is perfect for placing items and can easily tow a Lure boat anywhere. Able to be placed steadily in 700mm of water, GWM POER is a considerate product in the eyes of Lure enthusiasts. GWM POER has sponsored the Lure International Championship for two consecutive years. Its vehicle support for Lure contestants has been highly recognized.

As the NEXT-Gen Smart Safety Pickup, GWM POER adopts a user-centric approach and explores different circles to make its product an intimate all-scenario companion. Besides Lure, GWM POER has also probed into eight outdoor circles around the world, including cross-country activities, expeditions and camping, showing its all-scenario hardcore performance, and bringing infinite possibilities of diversified lifestyles to global users.

Equipped with three differential locks, crawling mode, tank U-turn, 7 all-terrain driving modes and other comprehensive off-road devices, GWM POER beat bad road conditions with ease during the Mount Everest Elevation Survey. The journey was tested by rain, snow, fog and other complicated weather. GWM POER crossed the snow-and-ice roads on the Kya Wu Lha Pass at 5,200 meters above sea level with 108 turns in Mount Everest National Park, paying tribute to the climber's spirit. GWM POER invited well-known commentators Ahmed Al Shehri and Hani Daghustani to drive across oases, deserts and castles in Saudi Arabia to highlight its powerful trafficability, extrication and loading power under the exotic charm. GWM POER, combining muscular vehicle body, smart technology, hardcore performance and high safety, restored the multiple dimensions of life with tents and motorcycles in South Africa and linked user emotions through the integration of scenario-based activities and life. In the future, GWM POER will also be fully integrated into the South African pickup culture through a series of sponsored joint activities across the sea fishing, cycling and camping circles.

Since its launch, GWM POER has accumulated tens of thousands of users and is highly recognized by the market. It has won the Chilean "Best Pickup of the Year", "The Car of the Year" issued by media authorities in Australia and New Zealand and other authoritative awards in succession. In the future, GWM POER will continue to optimize its products, innovate its usage scenarios, and create a cooler product experience for global users.

Photo -

CONTACT: Pupu Li, +86-13466544432,

21 uur geleden